Bora Pharmaceuticals to Expand Midwest Manufacturing Site

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Bora Pharmaceuticals announced on Aug. 5, 2025 that it plans to invest in the expansion manufacturing and packaging capabilities at the company’s Maple Grove, Minn. facility that it acquired in 2024 with the acquisition of Upsher-Smith Laboratories. The expansion is part of the company’s growth to meet the demand for oral solid dose products, increasing complex formulations, novel drug delivery technologies, and the shift from solid dosage to biologic formulations.

Expanded manufacturing capabilities

The first phase of the contract development and manufacturing organization’s (CDMO’s) investment will be a Gerteis Macro-Pactor at the site that will be followed by a broader buildout of 100,000 square feet of dedicated shell space to streamline high-volume production. The FDA-inspected manufacturing site will have on-site quality control laboratories and a dedicated development team.

“With pharmaceutical companies relying more heavily on specialized CDMO partners to scale production and maintain quality, top-tier manufacturing capacity and technical expertise are at a premium,” said J.D. Mowery, president of Bora’s CDMO business, in a press release (1). “Bora’s Maple Grove facility offers a unique opportunity for innovators to secure space in a state-of-the-art site staffed by experts in formulation development, tech transfer, and commercial manufacturing.”

“As we complete our transition from Upsher-Smith, we’re creating the infrastructure to deliver integrated manufacturing, packaging, and analytical services with the speed and quality our clients need,” shared Dennis Hall, vice president and general manager of the Maple Grove site, in the release. “As we expand our capabilities, we look forward to tapping into all the experience and talent in the area.”

New filling line at Canadian facility

In July 2025, Bora announced the installation of a high-performance filling line at its Mississauga, Ontario, Canada manufacturing facility to expand the company’s production capabilities, especially for dermatologic products in response to projected growth in the dermatologic market. The new tube-filling line can produce approximately 7 million to 15 million units pers year and can handle metal, plastic, and ABL tubes. The line can accommodate fill volumes from 2g to 150g and supports scalability in manufacturing vessels, specifically for semi-solid manufacture, that range in size from 2.5Kg to 3600Kg. Laser printing capabilities are suited for dermatologic applications, and the line, which is PODA and Track and Trace serialization qualified, can pack tubes into a wide range of cartons, then bundle, and automatically pack into shipping cases.

“This filling line complements our deep expertise in semi-solid formulations and strengthens our ability to help customers scale up efficiently,” John Lawrie, vice-president of Operations for Bora Pharmaceuticals, said in a press release (2). “The upgrade significantly expands our capacity, allowing us to address growing demand for high volume production not just from our current partners, but from the marketplace as a whole.”

References

1. Bora Pharmaceuticals. Bora Pharmaceuticals Announces Multi-Year Expansion for Midwest Manufacturing Site, as Upsher-Smith Entity Split is Finalized. Press Release. Aug. 5, 2025. https://bora-corp.com/bora-pharmaceuticals-announces-multi-year-expansion-for-midwest-manufacturing-site-as-upsher-smith-entity-split-is-finalized/
2. Bora Pharmaceuticals. Cutting-Edge Technology to Accelerate High-Volume Production; Mississauga Site to be Outfitted with Tube Filler this July. Press Release. July 16, 2025. https://bora-corp.com/bora-pharmaceuticals-adds-new-filling-line-to-canadian-manufacturing-facility/